Treatment of first-void urine with Aptima Transfer Solution increases detection of high-risk HPV E6/E7 mRNA

• Published in: Journal of virological methods 2019-05, Vol.267, p.48-52
• Main Authors: Arias, Manuel, Jang, Dan, Dockter, Janel, Ratnam, Sam, Shah, Anika, Elit, Laurie, Smieja, Marek, Lytwyn, Alice, Getman, Damon, Weinbaum, Barbara, Chernesky, Max
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aptima transfer solution; Cervical Intraepithelial Neoplasia - diagnosis; Cervical Intraepithelial Neoplasia - virology; Cervix Uteri - virology; Cross-Sectional Studies; Early Detection of Cancer - methods; Endopeptidase K - chemistry; Female; Histological Techniques; Histology; HPV mRNA; Humans; Male; Middle Aged; Oncogene Proteins, Viral - genetics; Papillomavirus Infections - diagnosis; Papillomavirus Infections - urine; Papillomavirus Infections - virology; Preservation, Biological; PreservCyt; RNA, Viral - isolation & purification; Sensitivity and Specificity; Specimen Handling - methods; Urine; Urine - chemistry; Uterine Cervical Neoplasms - diagnosis; Uterine Cervical Neoplasms - virology; Young Adult
• ISSN: 0166-0934; 1879-0984
• DOI: 10.1016/j.jviromet.2019.02.007

•Proteinase K treatment of female and male urine increased mRNA HPV positive rates.•Treated urine and PreservCyt cervical samples demonstrated good HPV agreement overall.•More women with abnormal cytology or neoplasia had HPV in the cervix than urine. Because of its non-invasive nature urine testing may enable increased screening for HPV in women who avoid cervical sampling. Comparisons have shown fewer HPV positives in urine. The objectives were to compare first-void urine (FVU) treated with proteinase K (PK) to untreated FVU and cervical samples collected from women attending a colposcopy clinic using an Aptima HPV mRNA assay, and comparing the HPV rates to cytology and pathology results. Female FVU (n = 433) was treated with Aptima Transfer Solution (ATS) containing PK within 24 h or after months of storage. Untreated female FVU samples were HPV-positive in 20.8–27.6% compared to 34.4–45.6% of ATS-treated FVU and 44.9–48.4% of PreservCyt samples. Good overall agreement for HR-HPV detection between ATS-FVU and PreservCyt was observed (81.1%; k 0.63). Validation of ATS treatment was performed on 356 male FVU, detecting 6.7% HPV positive compared to 3.4% of untreated samples (p = 0.059). Although HPV presence in ATS FVU and PreservCyt samples were similar, significantly more women with abnormal cervical cytology and histopathology were HPV-positive in cervical specimens than in ATS-treated FVU.